What is the main difference between Semax and Selank?

They act on different systems and are studied for opposite ends of cognitive state. Semax is an ACTH(4–7) analogue examined for effects on BDNF, attention and neuroprotection. Selank is a tuftsin analogue studied for anxiolytic effects through GABAergic modulation.

Why are they studied together?

Because the mechanisms are unrelated. Studying both allows researchers to examine engagement and calm at the same time, rather than pushing harder on a single pathway — a different question from studying either alone.

Does Semax raise cortisol, given it comes from ACTH?

Research indicates not. Semax is based on the ACTH(4–7) fragment, which retains the neuroactive portion of the molecule while the hormonal activity driving cortisol release is absent. That separation is a large part of why the fragment is of research interest.

How is Selank different from a benzodiazepine?

Research indicates Selank modulates the GABA system without binding the benzodiazepine receptor. Studies associate it with calming effects that lack the sedation, tolerance and dependence characteristic of that drug class — though it is a research compound, not an approved medicine.

Are they approved anywhere?

Both have been registered pharmaceuticals in Russia for decades — Semax since 1994 and Selank since 2009. Neither is approved by the FDA, EMA or TGA. These are research-grade compounds and are not approved for human or veterinary use.

Research Library›Comparisons›Semax vs Selank

Cognitive Comparison

Semax vs Selank: Opposite Ends of the Same Spectrum

Two synthetic neuropeptides from the same Moscow institute, often mentioned in the same breath. One is studied for sharpening attention, the other for taking the edge off — which is exactly why they are examined as a pair.

7 min read·5 studies cited·Updated July 2026

Quick Reference

Semax	ACTH(4–7) analogue — BDNF, attention
Selank	Tuftsin analogue — GABAergic, anxiolytic
Shared origin	Institute of Molecular Genetics, Moscow
Russian registration	Semax 1994 · Selank 2009
Status	Research use only — not TGA approved

The Short Answer

These two are studied at opposite ends of cognitive state. Semax derives from ACTH(4–7) — a fragment of the stress hormone with the hormonal activity removed — and research examines its effects on attention, memory and neurotrophic signalling. Selank derives from tuftsin, a small immune-signalling peptide, and is studied for anxiolytic effects.

One is examined for engagement, the other for calm. That complementary relationship is why they are studied together rather than as substitutes for one another.

	Semax	Selank
Derived from	ACTH(4–7) — a stress-hormone fragment	Tuftsin — an immune-signalling peptide
Main pathway studied	BDNF and NGF expression	GABAergic modulation
Research focus	Attention, memory, neuroprotection	Anxiety, stress response
Notable property	Acts without stimulating cortisol	Calming without benzodiazepine-type sedation
Registered in Russia	1994	2009
Western literature	Growing, still smaller than Russian record	Smaller again

Two Different Mechanisms

The two mechanisms, in plain language: picture the brain as an orchestra. Semax works on the musicians. The neurotrophic factors it influences — BDNF and NGF — are what the brain uses to build and maintain neurons, so the research question is whether the players themselves are well-rehearsed and responsive. Selank works on the volume in the hall. It acts on the GABA system, the brain’s main quieting signal, turning down the background noise so the music can be heard clearly. Better players, or less noise: two different problems, and fixing one does nothing about the other. That is the whole reason these two are studied side by side rather than treated as alternatives to each other.

Semax is studied chiefly for its influence on neurotrophic factors — BDNF and NGF, the proteins the brain uses to build and maintain neurons. Published rodent work reports increased BDNF expression in the cortex and hippocampus, the regions most involved in memory. Its ACTH origin is notable: the parent hormone drives cortisol release, but the fragment used in Semax has that hormonal activity removed, which is why research describes neuroprotective effects without the systemic stress response.

Selank works through a different system. Research indicates it modulates GABA signalling — the brain’s principal inhibitory, or calming, pathway — without binding the benzodiazepine receptor. That distinction is the point of interest: benzodiazepines act on that receptor and carry sedation, tolerance and dependence with them, and Selank is studied for GABAergic effects without those features.

Why the pairing is coherent: because the two act on unrelated systems — neurotrophic signalling on one side, inhibitory neurotransmission on the other — studying them together lets researchers examine both ends of cognitive state at once rather than pushing harder on a single mechanism.

That is a genuinely different research question from taking either alone, and it is the reasoning behind the Cognitive collection.

The Evidence Picture, Honestly

Both compounds occupy an unusual position. Each has been a registered pharmaceutical in Russia for decades — Semax since 1994, Selank since 2009 — which means a substantial body of clinical observation exists. Semax appears in the Russian List of Vital and Essential Medicines.

The caveat is that most of that literature is Russian-language and was produced under a different regulatory framework from Western drug approval. Neither compound is approved by the FDA, EMA or TGA. Western published work is growing but remains considerably smaller, and much of it is mechanistic or preclinical.

So the honest summary is: more real-world clinical use behind them than most research peptides, but less independently replicated Western trial data than that history might suggest.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain research, 2006. PubMed
Kolomin T, Shadrina M, Slominsky P, et al. “A new generation of drugs: synthetic peptides based on natural regulatory peptides.” Neuroscience and Medicine, 2013. Source
Zozulia AA, Neznamov GG, Siuniakov TS, et al. “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008. PubMed
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC genomics, 2014. PubMed
Kasian A, Kolomin T, Andreeva L, et al. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural neurology, 2017. PubMed